KIF5B and diabetes mellitus: KIF5B-deficient beta cells will thus serve as an ideal system for studying a Ca2+- or SFK-independent component of first-phase GSIS, which will contribute to next-generation diabetes therapeutics (Sola et al, 2015; Wang et al, 2021).